News

Media

Conferences

Publications

Clinical

Events

Resources

Targeted Therapy Treatment Innovations in AML : Episode 4

Video

August 26, 2021

Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP

Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.

EP: 1.Role of First Generation FLT3 Inhibitors in AML

EP: 2.Role of Second Generation FLT3 Inhibitors in AML

EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 5.Role of Venetoclax in Treatment of AML

EP: 6.Part 1: Practical Considerations For Venetoclax in AML

EP: 7.Part 2: Practical Considerations For Venetoclax in AML

EP: 8.5-Year Follow-Up Data For CPX-351 in AML

EP: 9.CPX-351 in Clinical Practice For AML

Related Videos

Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.

Image Credit: © nimito - stock.adobe.com

Image Credit: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com

Image Credit: © sofiko14 - stock.adobe.com

Image Credit: © hamad - stock.adobe.com

Consent Preferences

Clinical Forums

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.